Ethris GmbH, a clinical-stage biotechnology company developing next-generation RNA therapeutics and vaccines, on Friday announced a strategic collaboration with life science and clinical research company Thermo Fisher Scientific Inc (NYSE:TMO) to offer an integrated mRNA solution to biopharmaceutical developers.

The partnership combines Ethris' proprietary Stabilized Non-Immunogenic mRNA (SNIM RNA) and manufacturing technologies with Thermo Fisher Scientific's GMP-compliant production capabilities.

This collaboration aims to accelerate the development of mRNA-based medicines by enabling biopharma partners to move rapidly from research to clinical proof-of-concept.

Ethris' SNIM RNA technology addresses the typical instability and immunogenicity of mRNA, allowing repeated administration and sustained protein production.

The agreement also supports the continued optimization of Ethris' platform, including its lead candidate ETH47, which showed positive Phase 1 data in asthma treatment via nasal spray.

ETH47 demonstrated localized, dose-dependent protein expression without systemic exposure, confirming functional activity at the target site.

Ethris stated that the collaboration meets growing demand for scalable, high-quality mRNA technologies and enhances global accessibility.

The combined offering is positioned to serve a broad range of therapeutic applications, including protein replacement and vaccine development.